Can We See Significant Insider Ownership On The Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Share Register?

If you want to know who really controls Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I quite like to see at least a little bit of insider ownership. As Charlie Munger said ‘Show me the incentive and I will show you the outcome.

Brainstorm Cell Therapeutics is a smaller company with a market capitalization of US$86m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. Let’s delve deeper into each type of owner, to discover more about BCLI.

View our latest analysis for Brainstorm Cell Therapeutics

NasdaqCM:BCLI Ownership Summary, December 19th 2019
NasdaqCM:BCLI Ownership Summary, December 19th 2019

What Does The Institutional Ownership Tell Us About Brainstorm Cell Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it’s included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Brainstorm Cell Therapeutics already has institutions on the share registry. Indeed, they own 10% of the company. This suggests some credibility amongst professional investors. But we can’t rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Brainstorm Cell Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.

NasdaqCM:BCLI Income Statement, December 19th 2019
NasdaqCM:BCLI Income Statement, December 19th 2019

We note that hedge funds don’t have a meaningful investment in Brainstorm Cell Therapeutics. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of Brainstorm Cell Therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board; and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board, themselves.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

I can report that insiders do own shares in Brainstorm Cell Therapeutics Inc.. In their own names, insiders own US$6.6m worth of stock in the US$86m company. Ownership is clearly an important issue when it comes to investment selection. But ultimately, many risks exist within the business itself, rather than its shareholders. For example, we’ve discovered 3 warning signs for Brainstorm Cell Therapeutics (of which 1 is major) which any shareholder or potential investor should be aware of.

General Public Ownership

The general public, mostly retail investors, hold a substantial 73% stake in BCLI, suggesting it is a fairly popular stock. With this size of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to decline an acquisition or merger that may not improve profitability.

Private Company Ownership

Our data indicates that Private Companies hold 9.8%, of the company’s shares. It’s hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important.

I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.